Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Clinical Trial of CRISPR Delivered Anti-BCMA Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Multiple Myeloma

NCT07340853 is registered in ClinicalTrials.gov with Thomas Martin, MD as lead sponsor.

NCT NCT07340853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07340853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Clinical Trial of CRISPR Delivered Anti-BCMA Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Multiple Myeloma
Lead sponsor
Thomas Martin, MD
Phase
Phase 1
Overall status
Suspended
Start date
February 28, 2026
Completion date
May 25, 2043
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, recurrent multiple myeloma, refractory multiple myeloma